“The Role of Nutraceutical Supplements in the Treatment of Dyslipidemia”; Mark Houston, MD; The Journal of Clinical Hypertension; Volume 14; No. 2; February 2012.
In this blog I will focus solely on Omega-3 Fatty Acids because as Dr. Houston says: “observational, epidemiologic, and controlled clinical trials have shown significant reduction in serum triglycerides, VLDL, and LDL particle number and increased LDL and HDL particle size, as well as major reductions in all cardiovascular events.”
- Diet and Reinfarction Trial (DART): showed a decrease in mortality of 29% in men
- Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto (GISSI) prevention trial: found a decrease in total mortality of 20%, CV deaths of 30%, and sudden death of 45%.
- Kuppio Heart Study: showed 44% reduction in fatal and nonfatal CHD in patients in the highest quintile of omega 3 intake compared with the lowest quintile.
- Japan EPA Lipid Intervention Study (JELIS): addition of 1.8g of omega-3 fatty acids to a statin resulted in an additional 19% relative risk reduction in major coronary events and nonfatal MI and a 20% decrease in cerebrovascular accidents.
Effects on Lipids of Omega-3 Fatty Acids:
- Decreases LDL particle number.
- Converts smaller dense atherogenic LDL B to larger and more buoyant and less atherogenic LDL A particle size.
- Decreases Apo B levels.
- Decreases the rate of VLDL particles into the circulation.
- Net decrease in concentration of cholesterol carried by all atherogenic particles.
- Decreases in non-HDL cholesterol.
Other Effects of Omega-3 Fatty acids:
- Lower blood pressure and heart rate
- Improve heart rate variability.
- Improves insulin resistance and there are no significant changes in fasting glucose or HgA1c with long term treatment.
Recommended Dose: 3g of combined EPA and DHA at a 3:2 ratio (with gamma linoleic acid at 50% of the total EPA and DHA content)
**The combination of plant sterols and omega-3 fatty acids are synergistic in improving lipids and inflammation.